Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis

Cantó, Ester; Reverter, Ferrán; Morcillo-Suárez, Carlos; Matesanz, Fuencisla; Fernández, Óscar; Izquierdo, Guillermo; Vandenbroeck, Koen; Antigüedad, Alfredo Rodríguez; Urcelay, Elena; Arroyo, Rafael; Otaegui, David; Olascoaga, Javier; Sáiz, Antonio; Navarro, Arcadi; Sánchez, Antonio; Domı́nguez, Carmen; Caminero, Ana B.; Horga, Alejandro; Tintoré, Mar; Montalbán, Xavier; Comabella, Manuel

doi:10.1177/1352458511433063

Cited by 61 publications

(47 citation statements)

References 16 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, the minor rs4950928 G allele played a protective role in children and young adults with asthma [31]. Besides, the rs4950928 was also associated with primary progressive multiple sclerosis, with the increased CHI3L1 levels [32] implying that the minor G allele of rs4950928 conferred protection against central nervous system diseases, including AD. On the other hand, rs10399931, as a variant SNP (< 200 bp) at the transcription initiation site of CHI3L1 [33], was reported to be an effective marker for predicting the risk and severity of asthma in the Taiwanese population [34], which indicated that the T allele of rs10399931 C>T may be a risk factor for diseases.…”

Section: Discussionmentioning

confidence: 93%

Association of the Polymorphisms and Plasma Level of CHI3L1 with Alzheimer’s Disease in the Chinese Han Population: A Case-Control Study

Dai¹,

Gong²

2018

Neuropsychobiology

View full text Add to dashboard Cite

Objective: To investigate whether the polymorphisms and plasma level of chitinase-3-like protein 1 (CHI3L1) are associated with Alzheimer’s disease (AD) in the Chinese Han population. Methods: A total of 166 patients who were initially diagnosed with AD were enrolled as the case group, and 184 healthy subjects were recruited as the healthy controls. TaqMan® SNP genotyping assays were applied for the genotyping of rs4950928, rs10399931 and rs6691378. The plasma level of CHI3L1 was determined by enzyme-linked immunosorbent assay. Results: The CG+GG genotype of rs4950928 C>G is a protective factor for AD and could effectively reduce the severity of AD. Patients with the CT+TT genotype of rs10399931 C>T had a significantly increased risk of AD, and it apparently aggravated the severity of AD. Moreover, the plasma CHI3L1 level in AD patients was significantly higher than that in healthy controls, which was increased with the severity of AD. A Kaplan-Meier survival curve showed that significant differences in 5-year survival rates were found in AD patients in different genotypes of CHI3L1 rs4950928 C>G and rs10399931 C>T. The AD patients and healthy controls who carried the CG+GG genotype of rs4950928 C>G had lower plasma CHI3L1 levels than CC genotype carriers. However, the CT+TT genotype of rs10399931 in the AD patients had an elevated plasma level of CHI3L1 as compared with the CC genotype. Binary logistic regression analysis showed that the plasma level of CHI3L1, the CC genotype of rs4950928 C>G and the CT+TT genotype of rs10399931 C>T were risk factors for AD. Conclusion: Polymorphisms of the CHI3L1 gene (rs4950928 C>G and rs10399931 C>T) are associated with the risk and prognosis of AD and can affect the expression of CHI3L1 in plasma.

show abstract

Section: Discussionmentioning

confidence: 93%

Association of the Polymorphisms and Plasma Level of CHI3L1 with Alzheimer’s Disease in the Chinese Han Population: A Case-Control Study

Dai¹,

Gong²

2018

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…The optic coherent tomography provides information on axonal damage and can be used to monitor it. Potential prognostic markers are immunoglobulins M (IgM) [10] and neurofilaments in CSF [11,12], antimyelin [13], and chitinase-3-like protein 1 (CH3L1) [14] in blood and CSF [15]. These markers have to be validated before their use in clinical practice [9].…”

Section: Clinical Evaluation Of Musmentioning

confidence: 99%

Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine

Boccio

Rossi

Ioia

et al. 2016

Proteomics Clinical Apps

View full text Add to dashboard Cite

Personalized medicine is the science of individualized prevention and therapy. In the last decade, advances in high-throughput approaches allowed the development of proteomic and metabolomic studies in evaluating the association of genetic and phenotypic variability with disease sensitivity and analgesic response. These considerations have more value in case of multiple sclerosis (MuS), a multifactorial disease with high heterogeneity in clinical course and treatment response. In this review, we reported and updated about proteomic and metabolomic studies for the research of new candidate biomarkers in MuS, and difficulties in their clinical applications. We focused especially on the description of both "omics" approaches that, once integrated, may synergically describe pathophysiology conditions. To prove this assumption, we rebuilt interaction between proteins and metabolites described in the literature as potential biomarkers for MuS, and a pathway analysis of these molecules was performed. The result of such speculation demonstrated a strong convergence of proteomic and metabolomic results in this field, showing also a poorness of available tools for incorporating "omics" approaches. In conclusion, the integration of Metabolomics and Proteomics may allow a more complete characterization of such a heterogeneous disease, providing further insights into personalized healthcare.

show abstract

“…Some of the differentially regulated genes, such as the IL-7 receptor (Ilr7) (Gregory et al, 2007), tumor necrosis factor receptor superfamily 12, TNFRSF12/DR3 (Pappu et al, 2008) and TNF alpha induced protein 3 (TNFAIP3) (Prahalad et al, 2009) are known to confer susceptibility to multiple sclerosis. In addition, other candidates, such as chitinase-3-like (Chi3 l) (Canto et al, 2012;Comabella et al, 2010) and soluble TLR-4 co-receptor, sCD14 (Brettschneider et al, 2002) have been evaluated as biomarkers for MS, suggesting that R-flurbiprofen regulated several genes which are important in the human disease. Importantly, R-flurbiprofen per se did not affect gene expression in CFA control mice, which would be indicative of immunosuppressive effects but apparently, it blocks the activation process both of microglia/macrophages and of T cells and may help to maintain immune tolerance.…”

Section: Embo Molecular Medicinementioning

confidence: 99%

R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice

Schmitz

Bruin

Bishay

et al. 2014

Journal of Neuroimmunology

View full text Add to dashboard Cite

Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis

Abstract: These findings point to a role of CHI3L1 in patients with progressive forms of MS, particularly in those with PPMS.

Cited by 61 publications

References 16 publications

Association of the Polymorphisms and Plasma Level of CHI3L1 with Alzheimer’s Disease in the Chinese Han Population: A Case-Control Study

Association of the Polymorphisms and Plasma Level of CHI3L1 with Alzheimer’s Disease in the Chinese Han Population: A Case-Control Study

Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine

R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice

Contact Info

Product

Resources

About